Latvia is a high-priority country in the fight against tuberculosis (TB) in Europe, with an estimated TB incidence of 41 per 100 000 in 2015 [1]. In spite of an improving TB control programme [2] and cure rates reaching 80% for new and retreatment TB cases notified in 2014, multidrug-resistant (MDR-) TB (defined as TB resistant to rifampicin and isoniazid) rates in Latvia remain high [1]. An estimated 8% of new cases and 30% of retreatment TB cases were at least rifampicin-resistant (RR) in 2015 [1]. Cure rates in Latvia were 68% for the 2013 RR/MDR-TB cohort [1]. Of all the MDR-TB patients registered in 2015, 25% had extensively drug-resistant (XDR-) TB (defined as MDR-TB with additional resistance to a fluoroquinolone and a second-line injectable drug) [1]. Final treatment outcomes from the first cohort of delamanid MDR-TB patients in Latvia support its safety and efficacy http://ow.ly/6Mhy30fPv2f

中文翻译：

---

拉脱维亚耐多药和广泛耐药结核病患者接受含 delamanid 方案的最终治疗结果

拉脱维亚是欧洲抗击结核病 (TB) 的重点国家，估计 2015 年结核病发病率为每 10 万人 41 人 [1]。尽管结核病控制计划有所改进 [2] 并且 2014 年通报的新发和再治疗结核病例治愈率达到 80%，但拉脱维亚的耐多药 (MDR-) 结核病（定义为对利福平和异烟肼耐药的结核病）率仍然很高[1]。2015 年，估计有 8% 的新病例和 30% 的再治疗结核病病例至少对利福平耐药 (RR) [1]。拉脱维亚 2013 年 RR/MDR-TB 队列的治愈率为 68% [1]。在 2015 年登记的所有 MDR-TB 患者中，25% 患有广泛耐药 (XDR-) TB（定义为 MDR-TB，对氟喹诺酮类药物和二线注射药物具有额外耐药性）[1]。